If approved, vedolizumab — marketed as Entyvio — will be available in prefilled syringe and pen options.
Takeda based its application on its Visible 1 phase 3 study. In it, a significant proportion of patients treated with Entyvio achieved clinical remission compared to those receiving a placebo.
Takeda GI Business Unit senior vice president Uthra Sundaram said, “The availability of a subcutaneous option for maintenance therapy with vedolizumab, in addition to the currently approved intravenous formulation, would provide physicians and patients with greater flexibility on route of administration, if approved.”
More articles on gastroenterology:
Healthcare experts discuss investor interest in orthopedics — 5 key points
University of Maryland children’s medical device competition reveals 5 winners
RTI Surgical reports $9.1M net loss in Q1: 5 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.